All In Biotech

Drug Trial Radar · NCT06873321

VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization

Incidence of Venous Thromboembolism After Lower Limb Revascularization in Patients Receiving Rivaroxaban 2.5 Mg Bid + Aspirin 100 Mg Versus Single Antiplatelet Treatment - a Randomized Clinical Trial

Last checked: Nov 20, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Feb 24, 2024

Primary completion

Jul 20, 2025

Study completion Jul 30, 2025

Sponsor

Lead sponsor
Science Valley Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Venous thromboembolism (VTE) has a high prevalence in patients with multiple comorbidities undergoing complex surgical procedures. Sometimes, extended prophylaxis for VTE with KLMWH or direct oral anticoagulants (DOACs) is necessary. Currently, there is no consensus in the literature regarding the use of DOACs for extended VTE prophylaxis in patients undergoing lower limb revascularization (LLR). Objective: To evaluate the use of DOACs (already approved to reduce MACE and MALE) in VTE prophylaxis in patients undergoing LLR.

Conditions

  • Peripheral Arterial Disease
  • Venous Thormboembolism
  • Cardiovascular Diseases
  • Vascular Surgery Patient with PAD / Carotid Stenosis

Interventions

  • rivaroxaban 2.5 mg bid + aspirin 100 mgDrug

    rivaroxaban 2.5 mg bid + aspirin

  • clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open proceduresDrug

    comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. primary efficacy outcomeTime frame: 30 days
  2. primary safety outcomeTime frame: 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital das Clínicas, Federal University of Pernambuco

    Pernambuco, Pernambuco, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.